In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $35.00. Tyler Van Buren’s rating is based on a ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance represents the second in a series of negative revisions ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

You pay a one-off fee per logo, the price of which varies depending on the features you require (such as a transparent background or social media designs), and if you need the ability to amend ...

Moderna (NASDAQ:MRNA) was among the notable gainers on Wednesday after Oracle (NYSE:ORCL) Chairman Larry Ellison highlighted the AI's potential in the development of messenger RNA-based cancer ...

Biotechnology company Moderna (NASDAQ:MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to ...

Pharmaceutical company Moderna has been granted the funds to work on developing mRNA-based influenza vaccines, including for the strain causing the bird flu outbreak. Newsweek has contacted ...

↘️ MicroStrategy (MSTR): Cryptocurrencies pulled back after President Trump didn't mention crypto in his inauguration address. Shares in MicroStrategy, which also disclosed it had recently ...